Compare GSK plc (GSK) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Li Auto Inc — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while Li Auto Inc trades at $13.01 (market cap $12.31B). The key difference: GSK plc is far larger — about 8.2× Li Auto Inc's market cap, and GSK plc pays a 3.49% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals.
| GSK | LI | |
|---|---|---|
Market Cap | $101.34B | $12.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $31.80 |
52-Week Low | $36.20 | $11.74 |
Enterprise Value | $121.95B | $1.22B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Li Auto (LI) trades at $13.11, up 5.13% in 24 hours, with mixed technical signals showing bullish overall but bearish moving averages. Revenue declined to $112.31B in 2025 with net income of $1.12B, though profitability metrics like ROE remain negative at -2.56%. Recent news highlights vehicle delivery growth, with 30,895 units in June 2026, but competition and discounting pressures persist.
The stock offers potential upside to the $14.80 consensus price target, supported by analyst buy ratings (43.75%), but risks include volatile earnings, intense EV competition, and macroeconomic headwinds. Cash flow trends show improvement projected for 2026, yet negative margins and high P/E of 99.38 warrant caution for value-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
